Skip to main content
TipRanks
Go Ultimate75% OFF

Vertex Pharmaceuticals (VX1) Stock Statistics & Valuation Metrics

23 Followers

Total Valuation

Vertex Pharmaceuticals has a market cap or net worth of EUR 123.89B. The enterprise value is EUR 133.59B.

Market Cap
EUR 123.89B
Enterprise Value
EUR 133.59B

Share Statistics

Vertex Pharmaceuticals has 253,537,670 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
253,537,670
Owned by Insiders
0.20%
Owned by Institutions
94.30%

Financial Efficiency

Vertex Pharmaceuticals’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 18.54%.

Return on Equity (ROE)
0.21
Return on Assets (ROA)
0.15
Return on Invested Capital (ROIC)
18.54%
Return on Capital Employed (ROCE)
0.22
Revenue Per Employee
1.89M
Profits Per Employee
617.69K
Employee Count
6,400
Asset Turnover
0.47
Inventory Turnover
1.07

Valuation Ratios

The current PE Ratio of Vertex Pharmaceuticals is 34.39. Vertex Pharmaceuticals’s PEG ratio is 3.71.

PE Ratio
34.39
PS Ratio
10.51
PB Ratio
6.53
Price to FCF
42.64
Price to Operating Cash Flow
36.96
PEG Ratio
3.71

Income Statement

In the last 12 months, Vertex Pharmaceuticals had revenue of 12.07B and earned 3.95B in profits. Earnings per share was 15.46.

Revenue
12.07B
Gross Profit
10.27B
Operating Income
4.76B
Pretax Income
4.64B
Net Income
3.95B
EBITDA
4.87B
Earnings Per Share (EPS)
15.46

Cash Flow

In the last 12 months, operating cash flow was 3.69B and capital expenditures -492.30M, giving a free cash flow of 3.20B billion.

Operating Cash Flow
3.69B
Free Cash Flow
3.20B
Free Cash Flow per Share
12.63

Dividends & Yields

Vertex Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
2.35%
Earnings Yield
2.91%

Stock Price Statistics

Beta
0.30
52-Week Price Change
28.84%
50-Day Moving Average
462.58
200-Day Moving Average
420.19
Relative Strength Index (RSI)
56.27
Average Volume (3m)
43

Important Dates

Vertex Pharmaceuticals upcoming earnings date is Feb 09, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 02, 2026
Next Earnings Date
Feb 09, 2027
Ex-Dividend Date
―

Financial Position

Vertex Pharmaceuticals as a current ratio of 2.90, with Debt / Equity ratio of 10.88%

Current Ratio
2.90
Quick Ratio
2.46
Debt to Market Cap
0.00
Net Debt to EBITDA
-0.63
Interest Coverage Ratio
357.95

Taxes

In the past 12 months, Vertex Pharmaceuticals has paid 690.00M in taxes.

Income Tax
690.00M
Effective Tax Rate
0.15

Enterprise Valuation

Vertex Pharmaceuticals EV to EBITDA ratio is 27.79, with an EV/FCF ratio of 43.11.

EV to Sales
10.63
EV to EBITDA
27.79
EV to Free Cash Flow
43.11
EV to Operating Cash Flow
37.37

Balance Sheet

Vertex Pharmaceuticals has EUR 6.30B in cash and marketable securities with EUR 6.48B in debt, giving a net cash position of -EUR 175.10M billion.

Cash & Marketable Securities
EUR 6.30B
Total Debt
EUR 6.48B
Net Cash
-EUR 175.10M
Net Cash Per Share
-EUR 0.69
Tangible Book Value Per Share
EUR 39.31

Margins

Gross margin is 85.57%, with operating margin of 33.87%, and net profit margin of 30.61%.

Gross Margin
85.57%
Operating Margin
33.87%
Pretax Margin
36.64%
Net Profit Margin
30.61%
EBITDA Margin
38.24%
EBIT Margin
36.95%

Analyst Forecast

The average price target for Vertex Pharmaceuticals is EUR 552.92, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
EUR 552.92
Price Target Upside
13.49% Upside
Analyst Consensus
Strong Buy
Analyst Count
22
Revenue Growth Forecast
5.62%
EPS Growth Forecast
4.50%

Scores

Smart Score
8
AI Score
―